Figure 1.
Lymphoma status before and after CAR T-cell infusion. (A) PET/CT scans of patient 1 at the specified time points. Hypermetabolic pancreatic lesion is indicated at week −1 (arrow). (B) PET/CT scans of patient 2 demonstrating from left to right: hypermetabolic cecal mass and ileocolic lymphadenopathy lesions (arrows), no FDG avid lesion (remission), and development of new lesions in thoracic spine, left posterior abdomen, and in the right mid-abdomen (relapse) at weeks −1, +4, and +34 of axi-cel therapy, respectively. (C) PET/CT scan of patient 3 demonstrating from left to right: hypermetabolic left anterior mediastinal mass and multiple abdominal lymph nodes (arrows), interval decreasing in size and metabolic activity of these lesions (partial response), and progression at weeks −1, +4, and +12 of axi-cel therapy, respectively. FDG, fluorodexoglucose.

Lymphoma status before and after CAR T-cell infusion. (A) PET/CT scans of patient 1 at the specified time points. Hypermetabolic pancreatic lesion is indicated at week −1 (arrow). (B) PET/CT scans of patient 2 demonstrating from left to right: hypermetabolic cecal mass and ileocolic lymphadenopathy lesions (arrows), no FDG avid lesion (remission), and development of new lesions in thoracic spine, left posterior abdomen, and in the right mid-abdomen (relapse) at weeks −1, +4, and +34 of axi-cel therapy, respectively. (C) PET/CT scan of patient 3 demonstrating from left to right: hypermetabolic left anterior mediastinal mass and multiple abdominal lymph nodes (arrows), interval decreasing in size and metabolic activity of these lesions (partial response), and progression at weeks −1, +4, and +12 of axi-cel therapy, respectively. FDG, fluorodexoglucose.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal